Neurology News with information about conditions, treatments, current studies and breakthroughs.
Laxative Use Linked to Dementia
Recent studies show that regular use of over the counter laxatives has been linked to an increased risk of dementia. [...]
Chronic Pain Linked to Dementia
A recent study has found that people with chronic pain in various parts of the body have a higher risk [...]
Progressive Lateral Sclerosis
What is progressive lateral sclerosis? Progressive lateral sclerosis (PLS) is a type of motor neuron disease that affects the upper [...]
ALS
What is ALS? ALS stands for Amyotrophic Lateral Sclerosis, a progressive neurodegenerative disease that affects nerve cells in the brain [...]
When To Call 911
In which neurological conditions should you call 911? In the following neurological conditions, you should call 911 immediately: Stroke symptoms [...]
Aphasia
What is aphasia? Aphasia is a communication disorder that affects a person's ability to use or understand language, including spoken, [...]
- Exposure to Air Pollutants and Lewy Body and Parkinson Disease–Related Dementias June 12, 2026New JAMA Publication! Congratulations to Dimitry S. Davydow, MD, MPH, Gregory M. Pontone, MD, MHS, Michael S. Okun, MD, and Melissa J. Armstrong, MD on their publication “Exposure to Air Pollutants and Lewy Body and Parkinson Disease–Related Dementias,” which appears in JAMA Open Network. Long-term exposure to common air pollutants may increase the risk of developing Parkinson’s disease-related dementia and Lewy body dementia, according to…
- Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson’s Disease: ROSSINI Study 6-Month Interim Results June 10, 2026Congratulations Dr. Irene Malaty Dr. Malaty research “Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson’s Disease: ROSSINI Study 6-Month Interim Results,” was published in the May 2026 issue of Neurology and Therapy. Abstract Foslevodopa/foscarbidopa (LDp/CDp) is a nonsurgical 24-h continuous subcutaneous infusion for patients with advanced Parkinson’s disease (aPD) and motor fluctuations uncontrolled on…
- Diffusion MRI and α‐Synuclein Seed Amplification Status in Parkinson’s Disease June 8, 2026New Publication! Congratulations to Drs. Melissa J Armstrong, Nikolaus R. McFarland, Michael Okun and David Vaillancourt on the publication of “Diffusion MRI and α‐Synuclein Seed Amplification Status in Parkinson’s Disease,” which appears in the May edition of Annals of Neurology. Abstract Objective Positive α‐synuclein seed amplification assay (SAA) is a biomarker found in most people…
- Unveiling Reporting & Representation of Race and Ethnicity in Acute Interventional Neurology Trials: A Systematic Review June 5, 2026Congratulations on your new publication! Congratulations to Hector David Meza Comparan, Luciola Frota, Michael Mathelier, Carolina Maciel and Katharina Busl on the publication of “Unveiling Reporting & Representation of Race and Ethnicity in Acute Interventional Neurology Trials: A Systematic Review,” which appears in the April 8th edition of Neurology. Abstract Objective: To evaluate the extent and…
Get Social